{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:03:01Z","timestamp":1770746581107,"version":"3.49.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Surgery"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ijsu.2018.06.010","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T15:49:39Z","timestamp":1528818579000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis"],"prefix":"10.1097","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8509-2351","authenticated-orcid":false,"given":"Pan","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-4760","authenticated-orcid":false,"given":"Chuiguo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"1","key":"10.1016\/j.ijsu.2018.06.010_bib1","first-page":"7","article-title":"CA: a cancer journal for clinicians","volume":"67","author":"Siegel","year":"2017","journal-title":"2017"},{"issue":"1","key":"10.1016\/j.ijsu.2018.06.010_bib2","first-page":"7","article-title":"CA: a cancer journal for clinicians","volume":"68","author":"Siegel","year":"2018","journal-title":"2018"},{"issue":"1","key":"10.1016\/j.ijsu.2018.06.010_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","article-title":"EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur. Urol."},{"issue":"8","key":"10.1016\/j.ijsu.2018.06.010_bib4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the st gallen advanced prostate cancer consensus conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann. Oncol.: Official Journal of the European Society for Medical Oncology"},{"issue":"11","key":"10.1016\/j.ijsu.2018.06.010_bib5","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int. J. Clin. Pract."},{"issue":"9","key":"10.1016\/j.ijsu.2018.06.010_bib6","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","article-title":"Optimal management of metastatic castration-resistant prostate cancer: highlights from a european expert consensus panel","volume":"50","author":"Fitzpatrick","year":"2014","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"issue":"Suppl 6","key":"10.1016\/j.ijsu.2018.06.010_bib7","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Horwich","year":"2013","journal-title":"Ann. Oncol.: Offic. J. European Soc. Med. Oncol."},{"issue":"6","key":"10.1016\/j.ijsu.2018.06.010_bib8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J. Clin. Oncol.: Offic. J. Am. Soc. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ijsu.2018.06.010_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ijsu.2018.06.010_bib10","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijsu.2018.06.010_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Canc."},{"issue":"12","key":"10.1016\/j.ijsu.2018.06.010_bib12","first-page":"881","article-title":"[New guidelines to evaluate the response to treatment in solid tumors]","volume":"87","author":"Duffaud","year":"2000","journal-title":"Bulletin du cancer"},{"issue":"1","key":"10.1016\/j.ijsu.2018.06.010_bib13","first-page":"127","article-title":"Bayesian mixed treatment comparisons meta-analysis for correlated outcomes subject to reporting bias. Journal of the Royal Statistical Society Series C","volume":"67","author":"Liu","year":"2018","journal-title":"Applied statistics"},{"key":"10.1016\/j.ijsu.2018.06.010_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"24","key":"10.1016\/j.ijsu.2018.06.010_bib15","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.ijsu.2018.06.010_bib16","series-title":"A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials. London","author":"Dias","year":"2014"},{"issue":"28","key":"10.1016\/j.ijsu.2018.06.010_bib17","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J. Clin. Oncol.: Official Journal of the American Society of Clinical Oncology"},{"issue":"9747","key":"10.1016\/j.ijsu.2018.06.010_bib18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.ijsu.2018.06.010_bib19","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1200\/JCO.2008.16.9524","article-title":"Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer","volume":"26","author":"Machiels","year":"2008","journal-title":"J. Clin. Oncol.: Official Journal of the American Society of Clinical Oncology"},{"issue":"15","key":"10.1016\/j.ijsu.2018.06.010_bib20","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1200\/JCO.2005.12.187","article-title":"Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer","volume":"23","author":"Oudard","year":"2005","journal-title":"J. Clin. Oncol.: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.ijsu.2018.06.010_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117002","article-title":"A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer","volume":"10","author":"Zhou","year":"2015","journal-title":"PLoS One"},{"issue":"28","key":"10.1016\/j.ijsu.2018.06.010_bib22","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1200\/JCO.2017.72.4138","article-title":"Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J. Clin. Oncol.: Official Journal of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.ijsu.2018.06.010_bib23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/annonc\/mdm083","article-title":"Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer","volume":"18","author":"Eymard","year":"2007","journal-title":"Ann. Oncol.: Official Journal of the European Society for Medical Oncology"},{"issue":"9","key":"10.1016\/j.ijsu.2018.06.010_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1464-410X.2008.07779.x","article-title":"Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial","volume":"102","author":"Caffo","year":"2008","journal-title":"BJU International"},{"issue":"10","key":"10.1016\/j.ijsu.2018.06.010_bib25","first-page":"565","article-title":"[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]","volume":"35","author":"Mottet","year":"2011","journal-title":"Actas Urologicas Espanolas"},{"issue":"10","key":"10.1016\/j.ijsu.2018.06.010_bib26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2011.117","article-title":"The changing therapeutic landscape of castration-resistant prostate cancer","volume":"8","author":"Yap","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijsu.2018.06.010_bib27","article-title":"Advances in the management of castration resistant prostate cancer","volume":"355","author":"Ritch","year":"2016","journal-title":"Br. Med. J."},{"issue":"21","key":"10.1016\/j.ijsu.2018.06.010_bib28","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ijsu.2018.06.010_bib29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijsu.2018.06.010_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12672-014-0190-1","article-title":"Androgen receptor splice variants in the era of enzalutamide and abiraterone","volume":"5","author":"Nakazawa","year":"2014","journal-title":"Hormones & cancer"},{"key":"10.1016\/j.ijsu.2018.06.010_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2490-12-3","article-title":"Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience","volume":"12","author":"Nakano","year":"2012","journal-title":"BMC Urology"},{"issue":"12","key":"10.1016\/j.ijsu.2018.06.010_bib32","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00432-011-1052-7","article-title":"Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials","volume":"137","author":"Qi","year":"2011","journal-title":"J. Canc. Res. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ijsu.2018.06.010_bib33","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1200\/JCO.1999.17.6.1654","article-title":"Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone","volume":"17","author":"Osoba","year":"1999","journal-title":"J. Clin. Oncol.: Official Journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.ijsu.2018.06.010_bib34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.22811","article-title":"Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone","volume":"110","author":"Rosenberg","year":"2007","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.ijsu.2018.06.010_bib35","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1200\/JCO.2005.04.8207","article-title":"Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone","volume":"24","author":"Southwest Oncology","year":"2006","journal-title":"J. Clin. Oncol.: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ijsu.2018.06.010_bib36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ctrv.2016.09.017","article-title":"Early use of chemotherapy in metastatic prostate cancer","volume":"55","author":"Markowski","year":"2017","journal-title":"Canc. Treat Rev."},{"issue":"2","key":"10.1016\/j.ijsu.2018.06.010_bib37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J. Clin. Oncol.: Official Journal of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.ijsu.2018.06.010_bib38","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/annonc\/mdv129","article-title":"The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)","volume":"26","author":"Al-Batran","year":"2015","journal-title":"Ann. Oncol.: Official Journal of the European Society for Medical Oncology"},{"issue":"8","key":"10.1016\/j.ijsu.2018.06.010_bib39","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","article-title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","volume":"14","author":"Tannock","year":"2013","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ijsu.2018.06.010_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/annonc\/mds505","volume":"24","author":"Heidenreich","year":"2013","journal-title":"Ann. Oncol.: Official Journal of the European Society for Medical Oncology"},{"issue":"16","key":"10.1016\/j.ijsu.2018.06.010_bib41","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.ejca.2012.05.014","article-title":"Randomised phase II\/III study of docetaxel with or without risedronate in patients with metastatic castration resistant prostate cancer (CRPC), The Netherlands prostate study (NePro)","volume":"48","author":"Meulenbeld","year":"2012","journal-title":"Eur. J. Canc."},{"issue":"14","key":"10.1016\/j.ijsu.2018.06.010_bib42","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2012.46.4149","article-title":"Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Fizazi","year":"2013","journal-title":"J. Clin. Oncol.: Official Journal of the American Society of Clinical Oncology"},{"issue":"15_suppl","key":"10.1016\/j.ijsu.2018.06.010_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.5156","article-title":"A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer","volume":"27","author":"Petrylak","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ijsu.2018.06.010_bib44","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ijsu.2018.06.010_bib45","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","article-title":"Adding celecoxib with or without zoledronic acid for hormone-naive prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial","volume":"35","author":"Mason","year":"2017","journal-title":"J. Clin. Oncol.: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.ijsu.2018.06.010_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00002512-199507010-00006","article-title":"Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer","volume":"7","author":"Perry","year":"1995","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.ijsu.2018.06.010_bib47","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0022-5347(05)67815-9","article-title":"Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer","volume":"163","author":"Weitzman","year":"2000","journal-title":"J. Urol."},{"issue":"6C","key":"10.1016\/j.ijsu.2018.06.010_bib48","first-page":"4481","article-title":"Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience","volume":"25","author":"Boehmer","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ijsu.2018.06.010_bib49","series-title":"American Society of Clinical Oncology","article-title":"Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): preliminary results of HOPLITE trial","author":"Caffo","year":"2012"},{"issue":"39","key":"10.1016\/j.ijsu.2018.06.010_bib50","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004801","article-title":"Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"95","author":"Qin","year":"2016","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.ijsu.2018.06.010_bib51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4103\/aja.aja_40_17","article-title":"Role of chemotherapy in prostate cancer","volume":"20","author":"Nader","year":"2018","journal-title":"Asian Journal of Andrology"},{"issue":"9","key":"10.1016\/j.ijsu.2018.06.010_bib52","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/14740338.2014.939583","article-title":"Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program","volume":"13","author":"Castellano","year":"2014","journal-title":"Expet Opin. Drug Saf."},{"issue":"8","key":"10.1016\/j.ijsu.2018.06.010_bib53","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/CAD.0000000000000257","article-title":"Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience","volume":"26","author":"Francini","year":"2015","journal-title":"Anti Canc. Drugs"},{"issue":"4","key":"10.1016\/j.ijsu.2018.06.010_bib54","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.clgc.2015.01.010","article-title":"Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel","volume":"13","author":"Omlin","year":"2015","journal-title":"Clin. Genitourin. Canc."},{"issue":"5","key":"10.1016\/j.ijsu.2018.06.010_bib55","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3322\/caac.21141","article-title":"Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes","volume":"62","author":"Galsky","year":"2012","journal-title":"CA A Cancer J. Clin."}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743919118315024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743919118315024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:05:36Z","timestamp":1677081936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1743919118315024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":55,"alternative-id":["S1743919118315024"],"URL":"https:\/\/doi.org\/10.1016\/j.ijsu.2018.06.010","relation":{},"ISSN":["1743-9191"],"issn-type":[{"value":"1743-9191","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijsu.2018.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 IJS Publishing Group Ltd. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}